Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Nippon Chemiphar Co., Ltd. (4539:JPX), powered by AI.
Nippon Chemiphar Co., Ltd. is currently trading at ¥1,533. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Nippon Chemiphar Co., Ltd. on Alpha Lenz.
Nippon Chemiphar Co., Ltd.'s P/E ratio is 18.8.
“Nippon Chemiphar Co., Ltd. trades at a P/E of 18.8 (fair value) with modest ROE of 1.6%.”
Ask for details →Nippon Chemiphar Co., Ltd. is a pharmaceutical company focused on the development, manufacturing, and marketing of medical and pharmaceutical products. Its primary function is to provide innovative solutions in the healthcare industry, with a particular emphasis on generic drugs and research-driven proprietary medicines. The company plays a significant role in the healthcare sector by ensuring the availability of cost-effective medication and contributing to medical advancements through research and development. Nippon Chemiphar operates in various therapeutic areas, including cardiovascular, metabolic, and infectious diseases, enhancing patient outcomes with high-quality pharmaceuticals. Founded in Japan, the company adheres to stringent regulatory standards, ensuring safety and efficacy in all its offerings. Its market significance is underscored by its commitment to addressing medical needs and fostering alliances with global research institutions, thereby enhancing its competitive edge in the pharmaceutical landscape.
“Nippon Chemiphar Co., Ltd. trades at a P/E of 18.8 (fair value) with modest ROE of 1.6%.”
Ask for details →Nippon Chemiphar Co., Ltd. (ticker: 4539) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 855 employees. Market cap is $5.5B.
The current price is 1,533 with a P/E ratio of 18.81x and P/B of 0.29x.
ROE is 1.56% and operating margin is 1.86%. Annual revenue is $32.6B.